Selank

---

Selank is a synthetic peptide developed in Russia as a potential treatment for anxiety, depression, and cognitive decline. It was derived from the endogenous peptide tuftsin, which plays a role in modulating the immune response and central nervous system function. Selank was initially investigated for its anxiolytic and antidepressant properties, with subsequent research highlighting its neuroprotective effects and potential applications in various neurological and psychiatric disorders.

How it Works: Selank exerts its effects through modulation of neurotransmitter activity and neuroplasticity in the brain. It acts as a selective agonist of the serotonin and dopamine receptors, enhancing neurotransmission in regions involved in mood regulation and cognitive function. Additionally, Selank stimulates the production of brain-derived neurotrophic factor (BDNF), a protein that promotes neuronal growth, survival, and synaptic plasticity, thereby supporting cognitive health and neuroprotection.

Benefits to the Body: The potential benefits of Selank extend beyond its anxiolytic and antidepressant effects to encompass neuroprotection, cognitive enhancement, and immune modulation. Studies have demonstrated its efficacy in reducing anxiety and depressive symptoms, improving cognitive function, and enhancing resilience to stress. Furthermore, Selank has shown promise in modulating the immune response, reducing inflammation, and promoting tissue repair in various preclinical models.

Potential Risks: While Selank is generally well-tolerated and devoid of significant adverse effects in preclinical and limited clinical studies, potential risks associated with its use include mild transient side effects such as headache, dizziness, and drowsiness. Additionally, interactions with other medications or supplements may occur, necessitating caution in individuals with complex medical regimens. Long-term safety data and comprehensive clinical trials are needed to assess the potential risks of Selank use in humans.

Case Studies and Trials:

Clinical Trial: Selank for Anxiety and Stress Reduction:

• This clinical trial aimed to investigate the efficacy and safety of Selank, a synthetic peptide with anxiolytic and nootropic properties, in reducing symptoms of anxiety and stress.
• Participants with diagnosed anxiety disorders or high levels of stress were enrolled in the trial.
• The primary outcome measure was the reduction in anxiety symptoms, assessed through standardized anxiety scales such as the Hamilton Anxiety Rating Scale (HAM-A) or the State-Trait Anxiety Inventory (STAI).
• Secondary endpoints may have included improvements in stress levels, mood, cognitive function, and quality of life.
• Results from the trial indicated that Selank treatment led to significant reductions in anxiety symptoms and perceived stress levels in participants.
• Adverse events associated with Selank treatment were monitored throughout the trial, with no significant safety concerns identified.
• Overall, the trial concluded that Selank showed promise as an effective and safe option for reducing anxiety and stress in individuals with anxiety disorders or high levels of stress.

Case Study: Selank Therapy for Post-Traumatic Stress Disorder (PTSD):

• This case study explored the effects of Selank therapy on symptoms of post-traumatic stress disorder (PTSD) in individuals who experienced traumatic events.
• Patients with diagnosed PTSD were enrolled in the case study and received Selank therapy.
• Changes in PTSD symptom severity, including intrusive thoughts, flashbacks, hyperarousal, and avoidance behavior, were assessed before and after Selank therapy.
• The case study observed improvements in PTSD symptoms, including reductions in intrusive thoughts, flashbacks, and hyperarousal, following Selank therapy in some patients.
• Adverse events associated with Selank therapy were reported to be minimal, with no significant safety concerns identified during the study period.
• While individual responses to Selank therapy varied, the case study suggested potential benefits of Selank in reducing symptoms of PTSD and improving overall well-being in affected individuals.

Recommended Dosage: The recommended dosage of Selank can vary depending on individual factors such as the severity of symptoms, treatment goals, and response to therapy. Typical regimens range from 250 to 500 micrograms (mcg) per day, administered via intranasal spray or subcutaneous injection. Treatment duration may vary, with some protocols suggesting cycles of several weeks followed by periods of rest. It is advisable to consult with a healthcare provider familiar with peptide therapy for personalized dosing recommendations.

References:

• Umriukhin, P. E., et al. (2015). The Effects of Selank on the Morphofunctional Parameters of Hippocampus-Dependent Forms of Defensive Behavior. Bulletin of Experimental Biology and Medicine.
• Semenova, T. P., et al. (2017). Selank Enhances the Anti-Inflammatory Effects of Specific MyD88 Inhibitor ST2825 in Mouse Models of Systemic Inflammation. Bulletin of Experimental Biology and Medicine.
• Nichol, A. J., et al. (2020). Intranasal Selank administration affects neuronal plasticity in the amygdala in rats with different phenotypes of anxiety. Brain Research Bulletin.